Биология ва тиббиёт муаммолари 2024 №4 (155)

Maqola mavzusi

PROGNOSTIC SIGNIFICANCE OF HYPERURECEMIA IN THE DEVELOPMENT OF CHRONIC KIDNEY DISEASE (459-462)

Mualliflar

Tashkenbayeva Eleonora Negmatovna, Esankulov Mukhammad Olimovich

Muassasa

Samarkand State Medical University, Republic of Uzbekistan, Samarkand

Annotatsiya

A review of the literature is presented highlighting the role of hyperuricemia as a risk factor for the development of chronic kidney disease and one of the factors in the progression of existing kidney disease. Epidemiological information on the relationship between hyperuricemia and kidney damage is provided. The mechanisms of the damaging effect of uric acid on renal tissue, obtained in experiments and clinical conditions, are considered. The main directions of correction of hyperuricemia and the place of this therapy in the general strategy of nephroprotection have been deter-mined.

Kalit so'zlar

hyperuricemia, gout, chronic kidney disease, tubulointerstitial fibrosis.

Adabiyotlar

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Sep;84(3):1-150. 2. Couser WG, Remuzzi G, Mendis S, Tonelli M. The con-tribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011 Dec;80(12):1258-70. doi: 10.1038/ki.2011.368. Epub 2011 Oct 12. 3. Bellomo G., Venanzi S., Verdura C. et al. Association of uric acid with change in kidney function in healthy normo-tensive individuals. Am J Kidney Dis 2010; 56:264. 4. Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029. Epub 2013 Mar 29. 5. Kang DH, Chen W. Uric acid and chronic kidney dis-ease: new understanding of an old problem. Semin Nephrol. 2011 Sep;31(5):447- 52. doi: 10.1016/j.semnephrol.2011.08.009. 6. Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolution-ary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci US A. 2014 Mar 11;111(10): 3763-8. doi: 10.1073/pnas.1320393111. Epub 2014 Feb 18. 7. Richette P, Latourte A, Bardin T. Cardiac and renal pro-tective effects of uratelowering therapy. Rheumatology (Oxford). 2018 Jan 1; 57(suppl_1):i47-i50. doi: 10.1093/rheumatology/kex432. 9. Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017 Dec;36(12): 2637-2644. doi: 10.1007/s10067-017-3851-y. Epub 2017 Oct 10. Zhelyabina OV, Eliseev MS. Diet for gout and hyperuricemia. Scientific and practical rheumatology. 2017; 55(4):436-45. [Zhelyabina OV, Eliseev MS. Diet in gout and hyperuricemia. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017; 55(4):436-45. (In Russ.)]. doi: 10.14412/1995-4484-2017-436-445 11. Bjornstad P, Lanaspa MA, Ishimoto T, et al. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015 Sep;58(9): 1993-2002. doi:10.1007/s00125-015-3650-4. Epub 2015 Jun 7. 12. Mukhin N.A., Fomin V.V., Lebedeva M.V. Hyperuricemia as a component of cardiorenal syndrome. Ter Arch 2011; 6:5-12. 13. Obermayr RP, Temml C, Gutjahr G et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19:2407. 14. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19:1204. 15. Chonchol M., Shlipak MG, Katz R. et al. Relationship of uric acid with progression of kidney disease. Am J Kid-ney Dis 2007; 50:239. 16. Jalal DJ, Maahs DM, Hovind P. et al. Uric acid as a mediator of diabetic nephropathy. Semin Nephrol 2011; 31 (5): 459–465. 17. Yan Huang, Yu-Lin Li, He HuangLing et al. Effects of Hyperuricemia on Renal Function of Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Cohort Studies. PLoS One 2012; 7(6):e39457. 18. Johnson RS, Segal MS, Sriniivas T. et al. Essential hypertension, progressive renal disease and uric acid: a pathogenic link? J Am Soc Nephrol 2005; 16: 1990 19. Baker JF, Krishnan E., Chen L., Schumacher R. Serum uric acid and CVD: recent developments and where do they lead us? Am J Med 2005; 118:816. 20. Ikeda A., Ichikawa K., Ueno Y. et al. The association between serum uric acid and renal damage in a communi-ty-based population: the Takahata study. Clin Exp Nephrol 2012 Nov 27. [Epub ahead of print] 21. Kuo CF, See LC, Yu KH et al. Significance of serum uric acid levels in the risk of all-cause and cardiovascular mortality. Reumatology (Oxford) 2013; 52:127. 22. Niskanen LK, Laaksonen DE, Nyyssonen K. et al. Uric acid levels as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164:154. 23. Fang J., Alderman MN Serum uric acid and cardiovas-cular mortality the NHANES I Epidemiologic follow-up study, 1971—1992/National Health and Nutrition Exami-nation Survey. JAMA 2000; 283:2404. 24. Rizaev J. A. et al. The need of patients with systemic vasculitis and coronavirus infection in the treatment of periodontal diseases //Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny). – 2022. – Т. 25. – №. 4. – С. 40-45. 25. Rizaev J. A., Khaidarov N. K., Abdullaev S. Y. Current approach to the diagnosis and treatment of glossalgia (lit-erature review) //World Bulletin of Public Health. – 2021. – Т. 4. – С. 96-98. 26. Rizaev J. A., Maeda H., Khramova N. V. Plastic sur-gery for the defects in maxillofacial region after surgical resection of benign tumors //Annals of Cancer Research and Therapy. – 2019. – Т. 27. – №. 1. – С. 22-23. 27. Rizaev J. A., Khazratov A. I., Iordanishvili A. K. Morphofunctional characteristics of the mucous membrane of the masticatory apparatus in experimental carcinogenesis // Russian Journal of Dentistry. – 2021. – Т. 25. – №. 3. – С. 225-231. 28. Rizaev J. A., Rizaev E. A., Akhmadaliev N. N. Current View of the Problem: A New Approach to Covid-19 Treatment //Indian Journal of Forensic Medicine & Toxi-cology. – 2020. – Т. 14. – №. 4. 29. Rizaev J. A. et al. Oncoepidemiological assessment of the incidence and mortality of prostate cancer for the peri-od 2015-2020 in the cross section of the Republic of Uz-bekistan and individual regions // Open Access Repository. – 2023. – Т. 4. – №. 3. – С. 1108-1113. 30. Atakhanova L.E., Tsurko V.V., Buleeva I.M. and oth-ers. Gout: from etiology and pathogenesis to diagnosis and rational pharmacotherapy. Modern rheumatol 2007; 1: 13-18. 31. Chen CJ, Shi Y, Hearn A et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated monosodium urate crystals. J Clin Invest 2006; 116(8):2262–2271. 32. Yang Zhou, Li Fang, Lei Jiang et al. Uric Acid Induces Renal Inflammation via Activating Tubular NF kB Signal-ing Pathway. PLoS One 2012; 7(6):e39738. 33. Ryu ES, Kim MJ, Shin HS et al. Uric Acid-induced Phenotypic Transition of Renal Tubular Cells as a Novel Mechanism of Chronic Kidney Disease. Am J Physiol Re-nal Physiol 2013; 304(5):F471–480. 34. HuangW-Y., Li ZG. RGC-32 Mediates Transforming Growth FactorB2-induced Epithelial-Mesenchymal Transi-tion in Human Renal Proximal Tubular. Cell Biol Chem 2009; 284(14):942. 35. Kim SM, Choi YW, Seok HY et al. Reducing Serum Uric Acid Attenuates TGF-β(1)-Induced Profibrogenic Progression in Type 2 Diabetic Nephropathy. Arthritis Rheum 2012; 121 (3–4): e109–e121. 36. Kolz M., Johnson T., Teumer A. et al. Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations. PLoS Genet 2009; 5 (6): e1000504. 37. Anzai N., Enomoto A. Renal urate handling: clinical relevance of recent advances. Curr Rheumatol Rep 2005; 7 (3): 227–234. 38. Colin AJ Farguharson N. Allopurinol improves endo-thelial dysfunction in chronic heart failure. Circulation 2002; 106: 221–226. 39. Mazzali M., Kanellis J. Hyperuricemia induces a pri-mary renal arteriolopathy in rats by a BP-independent mechanism. Am J Physiol - Renal Physiol 2002; 282 (561–566): F991–F997. 40. Khosla UN, Zharikov S., Finch JI et al. Hyperuricemia induces endothelial dysfunction and vasoconstriction. Kidn Intern 2005; 67: 1739–1742. 41. Li J., Bertram JF Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrol-ogy (Carlton) 2010; 15 (5): 507–512. 42. Feig DI, Kang D., Johnson R. Uric acid and CV risk. N Engl J Med 2008; 358: 1811–1821. 43. Doehner W., Schoene N. Effects of xanthine oxidase inhibition with allopurinol on endothelial dysfunction and peripheral blood flow in hyperuricemic patients with heart failure: results from 2 placebocontrolled studies. Circula-tion 2002; 105 (22): 2619–2624.